Buflomedil interference with the monoclonal EMIT d. a. u. amphetamine/methamphetamine immunoassay

P. Papa, L. Rocchi, C. Mainardi, G. Donzelli

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

The interference of buflomedil with the monoclonal and polyclonal EMIT d. a. u. amphetamine immunoassays was investigated. Urine samples collected from 20 patients taking 600 mg of buflomedil daily gave false positive results with the monoclonal EMIT d. a. u. assay, as did urine specimens collected 2 hours after the first oral dose of buflomedil. Conversely, no false positive results occurred with the polyclonal EMIT d. a. u. amphetamine assay. Urine samples with buflomedil added at concentrations greater than 100 mg/l gave false positive results with the monoclonal immunoassay. Buflomedil concentrations found in the patient urines (56-400 mg/l) failed to correlate to EMIT assay responses: this result suggests that one or more buflomedil metabolites, besides the unchanged drug, probably interfere in the monoclonal EMIT d. a. u. assay.

Original languageEnglish
Pages (from-to)369-370
Number of pages2
JournalEuropean Journal of Clinical Chemistry and Clinical Biochemistry
Volume35
Issue number5
Publication statusPublished - 1997

Fingerprint

Methamphetamine
Amphetamine
Immunoassay
Assays
Urine
Enzyme Multiplied Immunoassay Technique
Metabolites
buflomedil
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

Buflomedil interference with the monoclonal EMIT d. a. u. amphetamine/methamphetamine immunoassay. / Papa, P.; Rocchi, L.; Mainardi, C.; Donzelli, G.

In: European Journal of Clinical Chemistry and Clinical Biochemistry, Vol. 35, No. 5, 1997, p. 369-370.

Research output: Contribution to journalArticle

@article{0c8f7a60fd274e8bb327c31d3b36d635,
title = "Buflomedil interference with the monoclonal EMIT d. a. u. amphetamine/methamphetamine immunoassay",
abstract = "The interference of buflomedil with the monoclonal and polyclonal EMIT d. a. u. amphetamine immunoassays was investigated. Urine samples collected from 20 patients taking 600 mg of buflomedil daily gave false positive results with the monoclonal EMIT d. a. u. assay, as did urine specimens collected 2 hours after the first oral dose of buflomedil. Conversely, no false positive results occurred with the polyclonal EMIT d. a. u. amphetamine assay. Urine samples with buflomedil added at concentrations greater than 100 mg/l gave false positive results with the monoclonal immunoassay. Buflomedil concentrations found in the patient urines (56-400 mg/l) failed to correlate to EMIT assay responses: this result suggests that one or more buflomedil metabolites, besides the unchanged drug, probably interfere in the monoclonal EMIT d. a. u. assay.",
author = "P. Papa and L. Rocchi and C. Mainardi and G. Donzelli",
year = "1997",
language = "English",
volume = "35",
pages = "369--370",
journal = "European Journal of Clinical Chemistry and Clinical Biochemistry",
issn = "0939-4974",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "5",

}

TY - JOUR

T1 - Buflomedil interference with the monoclonal EMIT d. a. u. amphetamine/methamphetamine immunoassay

AU - Papa, P.

AU - Rocchi, L.

AU - Mainardi, C.

AU - Donzelli, G.

PY - 1997

Y1 - 1997

N2 - The interference of buflomedil with the monoclonal and polyclonal EMIT d. a. u. amphetamine immunoassays was investigated. Urine samples collected from 20 patients taking 600 mg of buflomedil daily gave false positive results with the monoclonal EMIT d. a. u. assay, as did urine specimens collected 2 hours after the first oral dose of buflomedil. Conversely, no false positive results occurred with the polyclonal EMIT d. a. u. amphetamine assay. Urine samples with buflomedil added at concentrations greater than 100 mg/l gave false positive results with the monoclonal immunoassay. Buflomedil concentrations found in the patient urines (56-400 mg/l) failed to correlate to EMIT assay responses: this result suggests that one or more buflomedil metabolites, besides the unchanged drug, probably interfere in the monoclonal EMIT d. a. u. assay.

AB - The interference of buflomedil with the monoclonal and polyclonal EMIT d. a. u. amphetamine immunoassays was investigated. Urine samples collected from 20 patients taking 600 mg of buflomedil daily gave false positive results with the monoclonal EMIT d. a. u. assay, as did urine specimens collected 2 hours after the first oral dose of buflomedil. Conversely, no false positive results occurred with the polyclonal EMIT d. a. u. amphetamine assay. Urine samples with buflomedil added at concentrations greater than 100 mg/l gave false positive results with the monoclonal immunoassay. Buflomedil concentrations found in the patient urines (56-400 mg/l) failed to correlate to EMIT assay responses: this result suggests that one or more buflomedil metabolites, besides the unchanged drug, probably interfere in the monoclonal EMIT d. a. u. assay.

UR - http://www.scopus.com/inward/record.url?scp=0030969178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030969178&partnerID=8YFLogxK

M3 - Article

VL - 35

SP - 369

EP - 370

JO - European Journal of Clinical Chemistry and Clinical Biochemistry

JF - European Journal of Clinical Chemistry and Clinical Biochemistry

SN - 0939-4974

IS - 5

ER -